Those findings suggest a critical role for PTPN2 and PTPN22 in modulating intestinal microbiota composition and point towards a novel gene (PTPN2)-microbiota interaction directly affecting disease severity in IBD patients. This evidence concerns the gene PTPN22 and irritable bowel syndrome.